Richard Robson

Summary

Country: New Zealand

Publications

  1. ncbi The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis
    Richard Robson
    Christchurch Clinical Studies Trust, Christchurch Hospital, Christchurch, New Zealand
    Nephrol Dial Transplant 21:2556-62. 2006
  2. ncbi Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate
    Paul Snell
    Department of Research and Development, Roche Products Ltd, Welwyn Garden City, Hertfordshire AL7 3AY, UK
    Br J Clin Pharmacol 59:598-601. 2005
  3. ncbi Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Clin J Am Soc Nephrol 1:1211-5. 2006
  4. ncbi Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C
    Stuart K Roberts
    The Alfred Hospital, Melbourne, Australia
    Hepatology 48:398-406. 2008

Collaborators

Detail Information

Publications4

  1. ncbi The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis
    Richard Robson
    Christchurch Clinical Studies Trust, Christchurch Hospital, Christchurch, New Zealand
    Nephrol Dial Transplant 21:2556-62. 2006
    ..This study assessed the pharmacokinetics and tolerability of oseltamivir in ESRD patients undergoing maintenance haemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD)...
  2. ncbi Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate
    Paul Snell
    Department of Research and Development, Roche Products Ltd, Welwyn Garden City, Hertfordshire AL7 3AY, UK
    Br J Clin Pharmacol 59:598-601. 2005
    ..To compare the pharmacokinetics of oseltamivir and oseltamivir carboxylate in hepatically impaired patients and healthy subjects...
  3. ncbi Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Clin J Am Soc Nephrol 1:1211-5. 2006
    ..C.E.R.A. has a prolonged and comparable half-life after intravenous or subcutaneous injection, suggesting that extended administration intervals may be feasible in patients with CKD...
  4. ncbi Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C
    Stuart K Roberts
    The Alfred Hospital, Melbourne, Australia
    Hepatology 48:398-406. 2008
    ..Conclusion: These data support further studies of R1626 in combination with peginterferon alfa-2a and ribavirin for the treatment of patients with chronic HCV infection...